S&P 500 Record Close, Bank's Stumbles, Biotech's Continue Roar

S&P 500 Record Close

Independent macro and options research, published every trading day — $85/mo or $750/yr

Another day, another S&P 500 record close, we are sitting right near 2460, about 3.5 percent until our 2,550 target, first published on December 22nd, 2016. The S&P 500 is now up nearly 10 percent for the year, while the NASDAQ Composite is up slightly over 17 percent, and the NASDAQ 100 is up a blistering 20 percent. Technology has come back incredibly strong over the past week after a messy previous week. But Biotech’s are embarrassing the entire market, up nearly 33.5 percent so far in 2017. Wow!

^SPX data by YCharts

Don’t forget to subscribe to get more great content:

[wysija_form id=”2″]

Watch the 10 Big Investment Themes Video From December again:

Banks

The Banks did perform that well today, given the earnings results.

Bank Results

The stocks didn’t perform well either.

JPM Price data by YCharts

But next week is when the big results start coming in. If the market is going to keep moving higher it is going to need a strong earnings seasons to pull through.

Read our latest Premium Content:

Employment Run Down

Disclaimer:

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendation made during the past twelve months. Past performance is not indicative of future performance.

This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.

S&P 500 Record Close; Biotech’s Continue To Leave Other’s In The Dust

S&P 500 Record Close

Banks